Maximon

Maximon at bio:cap 2026 in Berlin

From 09–11 June 2026, bio:cap will bring together leaders from life sciences, AI, biotech, diagnostics and investment at CityCube Messe Berlin.
Maximon’s Founding Partner Marc P. Bernegger will be joining a panel discussion alongside Gregoire Biollaz, Aksana Labokha and Dr. Isabelle Schiffer to exchange perspectives on how capital, science and entrepreneurship can come together to turn breakthrough innovation into real-world impact.
At Maximon, we believe the future of longevity will be shaped at the intersection of science and business. Building impactful, science-based and scalable companies requires not only strong research, but also the right venture structures, investors and long-term conviction.
Looking forward to insightful discussions in Berlin on the future of life sciences, AI and health innovation.

📍 bio:cap – Life Science & AI Investival
🗓 09–11 June 2026
📌 CityCube Messe Berlin

𝐌𝐚𝐱𝐢𝐦𝐨𝐧 𝐚𝐭 𝐛𝐢𝐨:𝐜𝐚𝐩 2026 𝐢𝐧 𝐁𝐞𝐫𝐥𝐢𝐧

From 09–11 June 2026, bio:cap will bring together leaders from life sciences, AI, biotech, diagnostics and investment at CityCube Messe Berlin.

Maximon’s Founding Partner Marc P. Bernegger will be joining a panel discussion alongside Gregoire Biollaz, Aksana Labokha and Dr. Isabelle Schiffer, Ph.D to exchange perspectives on how capital, science and entrepreneurship can come together to turn breakthrough innovation into real-world impact.

At Maximon, we believe the future of longevity will be shaped at the intersection of science and business. Building impactful, science-based and scalable companies requires not only strong research, but also the right venture structures, investors and long-term conviction.

Looking forward to insightful discussions in Berlin on the future of life sciences, AI and health innovation.

📍 bio:cap – Life Science & AI Investival
🗓 09–11 June 2026
📌 CityCube Messe Berlin

The longevity field is advancing rapidly, driven by scientists, clinicians, founders, and investors who are turning decades of research into real-world impact. 🧬

has released its first-ever Rising Stars of Longevity list, highlighting 11 leaders who are helping shape the future of healthy aging across medicine, diagnostics, AI, biotech, and investment.

We are proud that , Founder of Maximon, was part of the expert panel helping evaluate the finalists alongside Andrea B. Maier, Nir Barzilai, Matt Kaeberlein, and Teresa Ghilarducci.

👏 Congratulations to the 2026 Rising Stars:
Dan Belsky, Evelyne Bischof, MD, PhD, Peter Fedichev, Celine Halioua, Jamie Justice, Ph.D., Nathan LeBrasseur, Morgan Levine, Dylan V. Livingston, Nicole Sirotin, MD DipABLM FACP, Alex Zhavoronkov, and Garri Zmudze.

What makes this list especially exciting is the diversity of perspectives represented. From biological age research and clinical translation to AI-driven discovery, preventive medicine, venture building, and investment.

Each of these leaders contributes to a broader movement: helping people live healthier for longer.

At Maximon, we believe the future of longevity will be built by those who combine rigorous science, entrepreneurial courage, and scalable solutions that can meaningfully improve healthspan.

It is inspiring to see this field gaining global recognition and even more exciting to see the people driving it forward.

Thank you to Business Insider and Hilary Brueck for spotlighting the innovators redefining how we think about aging, prevention, and human potential.💡

Dr. Tobias Reichmuth , Founding Partner at Maximon, has been named Founder of the Year 2026 by University of St.Gallen 🏆

The award was presented at START Summit in St. Gallen and recognises Tobias as a serial entrepreneur and investor who has helped build companies across climate finance, crypto and, more recently, longevity.
For us at Maximon, this recognition is especially meaningful because it highlights a mission we deeply believe in: turning cutting-edge science into real-world solutions that help people stay healthier for longer.
Through Maximon, Tobias has helped build ventures such as AVEA, AYUN and Frieda Health, all part of a broader effort to advance prevention, personalised health and healthy aging. Maximon’s mission is to empower entrepreneurs to build impactful, science-based and scalable companies in healthy aging and rejuvenation.
Congratulations, Tobias, on this well-deserved recognition. 👏

Is aging a disease or a natural process we can meaningfully influence?⏳

In SRF - Schweizer Radio und Fernsehen’s 𝘚𝘵𝘦𝘳𝘯𝘴𝘵𝘶𝘯𝘥𝘦 𝘗𝘩𝘪𝘭𝘰𝘴𝘰𝘱𝘩𝘪𝘦 𝘦𝘱𝘪𝘴𝘰𝘥𝘦 “𝘐𝘴𝘵 𝘈𝘭𝘵𝘦𝘳𝘯 𝘦𝘪𝘯𝘦 𝘒𝘳𝘢𝘯𝘬𝘩𝘦𝘪𝘵? Ü𝘣𝘦𝘳 𝘥𝘦𝘯 𝘛𝘳𝘢𝘶𝘮 𝘷𝘰𝘮 𝘭𝘢𝘯𝘨𝘦𝘯 𝘓𝘦𝘣𝘦𝘯”, Dr. Tobias Reichmuth joins Thomas Schulz (DER SPIEGEL) for a thoughtful follow-up conversation sparked by the recent SRF longevity documentary.

The interview goes beyond “biohacking headlines” and into the real questions the longevity movement has to answer:
• Where does prevention end and “optimization” begin?
• What’s scientifically realistic today and what still belongs in the future?
• How do we ensure longer lives translate into better lives (for individuals and for society)?

The conversation quickly shifts 𝐟𝐫𝐨𝐦 𝐭𝐡𝐞𝐨𝐫𝐲 𝐭𝐨 𝐬𝐨𝐦𝐞𝐭𝐡𝐢𝐧𝐠 𝐦𝐨𝐫𝐞 𝐩𝐞𝐫𝐬𝐨𝐧𝐚𝐥. Tobias shares his own perspective on longevity and a point we strongly agree with: there is 𝐧𝐨 𝐨𝐧𝐞-𝐬𝐢𝐳𝐞-𝐟𝐢𝐭𝐬-𝐚𝐥𝐥 𝐛𝐥𝐮𝐞𝐩𝐫𝐢𝐧𝐭.
What works for one person’s biology, lifestyle, and goals may not work for another’s. Longevity isn’t just a trend, it’s an individual journey shaped by context, genetics, behaviors, and priorities.

That’s also why measurement and personalization matter and we’re proud to back AYUN Clinic, where longevity is approached through data-driven diagnostics and tailored longevity check-ups and programs, helping people understand their current health status and make informed, realistic changes based on their markers and needs.

⬇️ Watch the discussion (🔗in comments) and share your view!

📺 Longevity is moving from niche to mainstream and Swiss public TV is asking the right questions.

SRF - Schweizer Radio und Fernsehen just released the documentary “Longevity – Auf der Suche nach einem erfüllten Leben”, following Mona Vetsch and Yves Bossart on a nearly year-long experiment to rethink daily habits, track key health metrics, and explore what it means to live longer and better.

What makes it compelling is that it doesn’t reduce longevity to numbers alone. It connects the science with the very human question of what a 𝐟𝐮𝐥𝐟𝐢𝐥𝐥𝐞𝐝 𝐥𝐢𝐟𝐞 looks like.
The film also offers great impressions from their two-day visit to the Longevity Investors Conference (LIC), a reminder that longevity is no longer just a research topic, but an ecosystem where science, entrepreneurship, and capital are converging to accelerate real-world progress.

We also appreciated seeing AYUN Clinic featured. AYUN stands for a proactive, data-driven approach to healthspan, combining advanced diagnostics with medical expertise and practical, personalized guidance. In the episode, assessments and tests were carried out by Dr. Dr. med. Oliver Boekels, Lead Physician at AYUN, helping translate complex biomarkers into clear next steps people can act on.

At Maximon, we build and back ventures that bring longevity science into real-world impact, with one clear focus: extend healthspan, not just lifespan.
Watch the whole coverage (🔗 in comments).

Building longevity isn’t just a lab story, it’s also a story of capital, conviction, and the big questions society needs to debate.

Swiss national TV, Radiotelevisione Svizzera (RSI) just covered the longevity space in Falò’s episode “𝘝𝘪𝘷𝘦𝘳𝘦 𝘧𝘪𝘯𝘰 𝘢 140 𝘢𝘯𝘯𝘪?” and it features Marc P. Bernegger and the Longevity Investors community.

The episode dives into what’s driving the global race for longer healthspans:
• why billions are flowing into longevity R&D
• what’s real science vs. hype
• and what it could mean if living to 120+ becomes more than a thought experiment

At Maximon, we build and back ventures that turn breakthrough science into real-world impact, responsibly, and with a long-term mindset.
If you’re curious to see how mainstream this topic has become, watch the segment (🔗 link in comments)

Maximon’s Founding Partners Dr. Tobias Reichmuth and Marc P. Bernegger were featured in finews.com: Top stories in connection with the Longevity Investors Lunch in Davos, where longevity science meets capital.

Beyond attending, Tobias and Marc are also the 𝐟𝐨𝐮𝐧𝐝𝐞𝐫𝐬 𝐚𝐧𝐝 𝐡𝐨𝐬𝐭𝐬 𝐛𝐞𝐡𝐢𝐧𝐝 𝐋𝐨𝐧𝐠𝐞𝐯𝐢𝐭𝐲 𝐈𝐧𝐯𝐞𝐬𝐭𝐨𝐫𝐬 𝐚𝐧𝐝 𝐢𝐭𝐬 𝐞𝐯𝐞𝐧𝐭𝐬, convening builders, researchers and investors to advance the healthspan agenda forward, grounded in science, and focused on real-world impact.

Some of the strongest themes highlighted:

• 𝐔𝐥𝐭𝐫𝐚-𝐩𝐞𝐫𝐬𝐨𝐧𝐚𝐥𝐢𝐳𝐞𝐝 𝐦𝐞𝐝𝐢𝐜𝐢𝐧𝐞: shifting from “average humans” to individual biology
• 𝐂𝐚𝐩𝐢𝐭𝐚𝐥 𝐛𝐮𝐢𝐥𝐝𝐢𝐧𝐠 𝐡𝐞𝐚𝐥𝐭𝐡𝐜𝐚𝐫𝐞 𝐢𝐧𝐟𝐫𝐚𝐬𝐭𝐫𝐮𝐜𝐭𝐮𝐫𝐞: from concierge care to integrated ecosystems
• 𝐌𝐞𝐝𝐢𝐜𝐢𝐧𝐞 3.0 𝐚𝐧𝐝 𝐀𝐈-𝐞𝐧𝐚𝐛𝐥𝐞𝐝 𝐩𝐫𝐞𝐯𝐞𝐧𝐭𝐢𝐨𝐧: moving from reactive care to proactive optimisation
A needed reminder to stay evidence-based, including caution around 𝐰𝐞𝐥𝐥𝐧𝐞𝐬𝐬 𝐈𝐕𝐬 and questionable supplementation

Tobias and Marc also delivered the 𝐜𝐥𝐨𝐬𝐢𝐧𝐠 𝐬𝐩𝐞𝐞𝐜𝐡, reflecting on what it takes to turn frontier science into scalable healthspan outcomes.

🔗 We’ll share the article and event background links in the comments.

Our Founding Partner Marc P. Bernegger sat down with GstaadLife Magazine for a thoughtful conversation about what’s changing in longevity and what should change next.

What we appreciate about the interview is its focus on 𝐬𝐮𝐛𝐬𝐭𝐚𝐧𝐜𝐞 𝐨𝐯𝐞𝐫 𝐬𝐭𝐨𝐫𝐲𝐭𝐞𝐥𝐥𝐢𝐧𝐠:

• 𝐑𝐢𝐠𝐨𝐮𝐫 𝐨𝐯𝐞𝐫 𝐡𝐲𝐩𝐞: longevity needs measurable outcomes, strong science, and responsible delivery and not “miracle” marketing.

• 𝐅𝐫𝐨𝐦 𝐧𝐢𝐜𝐡𝐞 𝐭𝐨 𝐦𝐚𝐢𝐧𝐬𝐭𝐫𝐞𝐚𝐦: real impact comes when proven tools become accessible, affordable, and integrated into everyday healthcare.

• 𝐇𝐞𝐚𝐥𝐭𝐡𝐬𝐩𝐚𝐧 𝐢𝐬 𝐭𝐡𝐞 𝐩𝐨𝐢𝐧𝐭: extending life only matters if we extend quality of life with prevention, diagnostics, and interventions that people can actually use.

• 𝐀 𝐟𝐢𝐞𝐥𝐝 𝐦𝐚𝐭𝐮𝐫𝐢𝐧𝐠 𝐟𝐚𝐬𝐭: the tone is shifting toward standards, scalability, and long-term value creation, exactly where the industry needs to go.

If you want a great read that cuts through the noise (and captures the spirit of the Longevity Investors Conference in Gstaad), this one is worth your time.
👇 Read it here (link in comments)

𝐍𝐞𝐰 𝐨𝐧 𝐭𝐡𝐞 𝐌𝐚𝐱𝐢𝐦𝐨𝐧 𝐛𝐥𝐨𝐠: 𝐁𝐢𝐭𝐜𝐨𝐢𝐧 𝐦𝐞𝐞𝐭𝐬 𝐋𝐨𝐧𝐠𝐞𝐯𝐢𝐭𝐲 - 𝐖𝐡𝐞𝐫𝐞 𝐝𝐢𝐬𝐫𝐮𝐩𝐭𝐢𝐨𝐧 𝐦𝐞𝐞𝐭𝐬 𝐝𝐞𝐟𝐢𝐚𝐧𝐜𝐞 ₿ 🧬

We just published a deeper write-up of Marc P. Bernegger’s talk from Lugano’s Plan ₿ Forum and why the overlap between crypto and longevity is becoming an investable, buildable frontier.

In the article, we explore:
• 𝐖𝐡𝐲 “𝐟𝐢𝐧𝐚𝐧𝐜𝐢𝐚𝐥 𝐞𝐧𝐭𝐫𝐨𝐩𝐲” 𝐚𝐧𝐝 “𝐛𝐢𝐨𝐥𝐨𝐠𝐢𝐜𝐚𝐥 𝐝𝐞𝐜𝐚𝐲” 𝐫𝐡𝐲𝐦𝐞 (and why both are being challenged)
• How crypto’s builder mindset is showing up in 𝐚𝐠𝐞 𝐫𝐞𝐯𝐞𝐫𝐬𝐚𝐥, 𝐜𝐫𝐲𝐨𝐧𝐢𝐜𝐬, 𝐚𝐧𝐝 𝐫𝐚𝐝𝐢𝐜𝐚𝐥 𝐥𝐢𝐟𝐞 𝐞𝐱𝐭𝐞𝐧𝐬𝐢𝐨𝐧
• How 𝐃𝐞𝐒𝐜𝐢 (Decentralized Science) is reshaping research funding and collaboration and what that could mean for biotech breakthroughs
• What this convergence means for founders, investors, and anyone thinking long-term

If you’re curious where capital, coordination, and science are heading next, have a look into it!
👉 𝐑𝐞𝐚𝐝 𝐭𝐡𝐞 𝐟𝐮𝐥𝐥 𝐛𝐥𝐨𝐠 𝐚𝐫𝐭𝐢𝐜𝐥𝐞 on Maximon’s website!